Basilea announces exclusive license and option agreement for potential first-in-class clinical-stage antibacterial agent
Exclusive license to evaluate tonabacase in preclinical studiesExclusive option to license tonabacase at pre-agreed terms Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, October 3...